Public Market Listing
9887 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (3 total) 3 Total Assets
0 Approved
0 Phase 3 / Filed
3 Phase 1–2 / Early
3 Diseases
Disease: All diseases (3) Non-Small Cell Lung Cancer (1) Multiple Myeloma (1) Systemic Lupus Erythematosus (1)
Stage: All stages (3) Approved / Phase 4 (0) Phase 3 / Filed (0) Phase 2 Phase 1 / Preclinical
Quick filter: All (3) Non-Small Cell Lung Cancer (1) Multiple Myeloma (1) Systemic Lupus Erythematosus (1)
Showing 3 of 3 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 2 PD-L1 + 4-1BB (CD137) Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1/2 GPRC5D x CD3 Multispecific antibody
Phase 1 BDCA2 (CLEC4C) / TACI Protein / enzyme therapeutic
Systemic Lupus Erythematosus
Upcoming events (12 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (3) December 2026 (3) Opamtistomig Phase 1/2 Advanced Solid Tumor Est. primary completion 2026-12 ·
NCT05170958 ·
CT.gov ↗ What to watch
Opamtistomig Phase 2 Advanced Solid Tumour Est. primary completion 2026-12-24 ·
NCT06783647 ·
CT.gov ↗ What to watch
Opamtistomig Phase 1/2 Advanced Neuroendocrine Carcinoma Est. primary completion 2026-12-28 ·
NCT06157827 ·
CT.gov ↗ What to watch
2027 (4) October 2027 (1) Opamtistomig Phase 1/2 Advanced Melanoma Est. primary completion 2027-10-30 ·
NCT07099430 ·
CT.gov ↗ What to watch
December 2027 (3) Opamtistomig Phase 1/2 Ovarian Cancer Est. primary completion 2027-12-25 ·
NCT07042802 ·
CT.gov ↗ What to watch
Opamtistomig Phase 2 Advanced Solid Tumour Est. primary completion 2027-12-26 ·
NCT07111546 ·
CT.gov ↗ What to watch
Opamtistomig Phase 1/2 Triple Negative Breast Cancer Est. primary completion 2027-12-31 ·
NCT07281976 ·
CT.gov ↗ What to watch
2028 (2) May 2028 (1) Opamtistomig Phase 2 Advanced Solid Tumour Est. primary completion 2028-05-30 ·
NCT07390383 ·
CT.gov ↗ What to watch
December 2028 (1) Opamtistomig Phase 2 Advanced Solid Tumour Est. primary completion 2028-12-26 ·
NCT07331155 ·
CT.gov ↗ What to watch
2029 (1) September 2029 (1) LBL-034 Phase 1/2 Relapsed/Refractory Multiple Myeloma Est. primary completion 2029-09-20 ·
NCT06049290 ·
CT.gov ↗ What to watch
2030 (2) September 2030 (1) Opamtistomig Phase 1/2 Metastatic Colorectal Carcinoma Est. primary completion 2030-09-04 ·
NCT07791758 ·
CT.gov ↗ What to watch
December 2030 (1) Opamtistomig Phase 3 Advanced Extrapulmonary Neuroendocrine Carcinoma Est. primary completion 2030-12-22 ·
NCT07720193 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (1) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
10 July 2026 Priority review Opamtistomig China's CDE accepts the opamtistomig BLA for EP-NEC into priority review Financial reports Quarterly & interim (1)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-Q1 — $8.0M $59M $10M report ↗
Annual history (1 year)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $0 $26M — $10M report ↗
Nanjing Leads Biolabs Co.,Ltd reported revenue of $0M, R&D spend of $25.89M, and a net loss of $41.89M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text